At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
Cunermuspir +1 moredrug
Likely dose
Cunermuspir 6.06 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled, Parallel Study Evaluating the Safety and Efficacy of Cunermuspir on Energy, Strength, Fatigue and Discomfort in Subjects With Nerve or Muscle Pain
In Brief
A Phase 2 clinical trial evaluating Cunermuspir and Placebo for Neuralgia and Myalgia. Completed, enrolled 56 participants across 1 site.
Detailed Summary
Male and female participants were selected based on chronic neuromuscular pain. Patients were instructed to take two doses of the placebo or cuprous nicotinic acid chelate Cunermusmir twice a day for 28 days. Hypothesis: Cunermuspir would improve quality of life as determined by several questionnaires.
Study Details
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
Primary CompletionMay 2014
Study CompletionSep 2014
First PostedFeb 2021
TodayJul 2026
First PostedFeb 3, 2021
Enrollment StartJan 28, 2014
Primary CompletionMay 28, 2014
Study CompletionSep 29, 2014
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.4 years ago
Interventions
Cunermuspirdrug
Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide
Placeboother
same non-medical ingredients and encapsulation as Intervention 1